www.reflexion.com/Healthcare / Medical DevicesFounded: 2009Funding to Date: $546.33MM
RefleXion is a developer of a biology-guided radiotherapy system that aims to create a significant change in strategy from single tumor therapy to the ability to treat multiple tumors in the same treatment session in cancers that have metastasized. The company’s SCINTIX® technology has a mission of tracking period tumor and non-tumor motion to reach its goal of creating a dual treatment modality. RefleXion was founded by Akshay Nanduri and Sam Mazin in 2009 and is headquartered in Hayward, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/15/2023 | Series F | $32.74MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
21,839,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series E-X | $18.01MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
7,597,170
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series D-X | $20.47MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
10,734,817
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series D-1-X | $6.55MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
2,872,489
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series C-X | $16.8MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
9,928,010
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series B-X | $8.51MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
7,891,388
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
11/15/2023 | Series A-X | $1.92MM | $xx.xx | $1.34B | The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand | |
Price per Share
$xx.xx
Shares Outstanding
5,583,233
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, Pictet, Square Point Capital, Ally Bridge, Pfizer Ventures, Johnson & Johnson Innovation, T.Rowe Price Associates, Venrock, Catalio, Hillenbrand
|
||||||
03/10/2022 | Series E | $110MM | $xx.xx | $785.79MM | Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation | |
Price per Share
$xx.xx
Shares Outstanding
46,402,813
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Group, Venrock, Pfizer Ventures Investments, Johnson & Johnson Innovation
|
||||||
03/02/2021 | Series D-1 | $40MM | $xx.xx | $650.69MM | Ally Bridge Group | |
Price per Share
$xx.xx
Shares Outstanding
17,544,898
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Ally Bridge Group
|
||||||
04/16/2020 | Series D | $125MM | $xx.xx | $496.89MM | The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation | |
Price per Share
$xx.xx
Shares Outstanding
65,567,269
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
|
||||||
04/04/2018 | Series C | $102.6MM | $xx.xx | $322.47MM | The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation | |
Price per Share
$xx.xx
Shares Outstanding
60,639,366
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Rise Fund, T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group, Venrock, Pfizer Venture Investments, Johnson & Johnson Innovation
|
||||||
07/19/2016 | Series B | $52MM | $xx.xx | $118.39MM | KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation | |
Price per Share
$xx.xx
Shares Outstanding
48,199,870
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
KCK Group, Venrock, Pfizer Venture Investments, Sofinnova Partners, Johnson & Johnson Innovation
|
||||||
04/04/2014 | Series A | $11.73MM | $xx.xx | $19.55MM | Sofinnova Partners, Pfizer Venture, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
34,101,874
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Sofinnova Partners, Pfizer Venture, Venrock
|